KalVista Pharmaceuticals (KALV) Cash from Investing Activities (2014 - 2025)

KalVista Pharmaceuticals (KALV) has 12 years of Cash from Investing Activities data on file, last reported at $21.3 million in Q3 2025.

• For the quarter ending Q3 2025, Cash from Investing Activities fell 42.79% year-over-year to $21.3 million; the trailing twelve-month figure through Jul 2025 stood at $103.8 million (up 254.49% YoY), and the FY2025 full-year result was $91.0 million, up 207.44% from the prior year.
• Cash from Investing Activities climbed to $21.3 million in Q3 2025, from -$3.3 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $48.7 million in Q4 2024 to a low of -$166.5 million in Q2 2021.
• A 5-year average of -$2.3 million and a median of $13.9 million in 2021 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities surged 176.93% in 2021 and sank 1931.98% in 2024, its largest moves.
• Tracing KALV's Cash from Investing Activities over 5 years: stood at $17.6 million in 2021, then gained by 13.91% to $20.1 million in 2022, then surged by 42.08% to $28.6 million in 2023, then surged by 70.45% to $48.7 million in 2024, then slumped by 56.32% to $21.3 million in 2025.
• Business Quant data shows KALV's Cash from Investing Activities at $21.3 million in Q3 2025, -$3.3 million in Q2 2025, and $48.7 million in Q4 2024.